|
|
home > ebr > summer 2007 > m&a and licensing – two journeys, same destination |
 |
 |
PUBLICATIONS |
European Biopharmaceutical Review
|
To increase the number of products on the market, biotech companies are radically rethinking the way they view the relationship between licensing and M&A opportunities. Gavin Weir and Isabella Roberts at Simmons & Simmons examine this forward-thinking new trend
Pharmaceutical companies are under increasing pressure to deliver growing profits to shareholders. Patent expiry, pricing controls, stringent regulatory requirements and consolidation of generics continue to present significant obstacles, while stocking product pipelines and bringing new drugs to market also present serious challenges. But now more than ever there are fewer new product candidates with blockbuster potential in development.
Research commissioned by Simmons & Simmons, published May 2007, asked senior executives from 20 of the leading global pharmaceutical companies to identify the challenges facing the industry as well as the emerging trends, and in particular looked at licensing and M&A opportunities.
The survey indicates that:
- Pharmaceutical companies must acquire rights to new, often speciality products at an earlier stage and, in some cases, with less market potential than they would previously have considered
- Licensors expect licensees to assume more risk, but often with less outright control over development
- Deal structures are becoming more innovative to enable licensees to remain competitive – increased collaboration on developmental decision making, co-promotion and advanced royalty sharing are all now important elements
- M&A deals are on the increase, with the majority of activity directed towards the acquisition of biotechs or smaller pharma companies, rather than peer-to-peer mergers (with a few notable exceptions)
- Traditional boundaries between M&A and licensing are becoming blurred as a greater number of licensing deals involve M&A type structures and the risk profiles of the two become more aligned
- Target identification, valuation and negotiation of deal terms are major challenges facing pharma executives
- More than three-quarters of pharma executives interviewed believe that biotech and new product valuations have not yet peaked
These findings demonstrate that the risk/reward balance is shifting in favour of biotechs, while the focus of pharmaceutical companies is very much on identifying M&A and licensing targets, and getting the deal done to maximise shareholder value. Flexibility and speed in deal-making are crucial to success.
Deal volume and complexity are likely to increase, with pharmaceutical companies spreading their investment risk across a larger portfolio of product candidates and a wider spectrum of development phases. This in turn will lead to greater challenges for internal projects and their funding allocation, with divestment of projects where candidates fail to meet expectations or where anti-trust regulations require it. |
Read full article from PDF >>
|
 |
 |
 |
Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | |
|
|
 |
News and Press Releases |
 |
Gelomics Partners With Rousselot Biomedical to Create the World’s First, Ready-to-Use 3D Cell Culture Kits Based on X-PURE® GelMA
Irving, United States, 16th November 2022 / Sciad Newswire /
Darling Ingredients’ Health Brand, Rousselot, the global leader in
collagen-based solutions, and Gelomics, the world-leading provider of
fully integrated 3D cell, organoid and tissue culture technologies, have
entered into a cobranding partnership. Rousselot Biomedical will supply
Gelomics with its X-Pure GelMA (gelatin methacryloyl), a photo
cross-linkable extracellular matrix, for use in Gelomics’ LunaGel™ 3D
Tissue Culture System.
More info >> |
|

 |
White Papers |
 |
Cleaning Validation: What do you need to consider to ensure a successful outcome?
RSSL
Cross contamination must be avoided in the Pharmaceutical industry at all costs and successful cleaning validation ensures that patients are not put at risk due to cross contamination.
The process can be divided into a number of sections each of which must be fully understood and areas of concern addressed to ensure a successful outcome across the entire process. This spans both the manufacturing and subsequent analytical and microbological support.
The data used to confirm a positive/successful cleaning validation is underpinned by the results of validated analytical methods. It is essential that these results are truly representative as patient safety is based upon the absence of equipment residues.
So what are those areas of concern, what affects your ability to get a successful outcome and what do you need to consider when carrying out a Cleaning Validation exercise?
More info >> |
|
|